Literature DB >> 17296760

Influence of neutropenia on the course of serotype 8 pneumococcal pneumonia in mice.

Matthew Marks1, Tamika Burns, Maria Abadi, Beza Seyoum, Justin Thornton, Elaine Tuomanen, Liise-anne Pirofski.   

Abstract

Polymorphoneutrophils (PMNs) are important effector cells in host defense against pneumonia. However, PMNs can also induce inflammation and tissue damage. To investigate the contribution of PMNs to host defense against pneumococcal pneumonia, we determined the effect of the PMN-depleting rat monoclonal antibody RB6-8C5 (RB6) on survival and inflammatory and cellular response in the lungs to a lethal intranasal infection with a serotype 8 pneumococcus in BALB/c mice. Control mice received rat immunoglobulin G (rIgG). Strikingly, the survival of RB6-treated mice was significantly prolonged compared to that of rIgG-treated mice. Although the numbers of CFU in the lungs were statistically similar in both groups 4, 24, and 32 h after infection, rIgG-treated mice developed higher levels of bacteremia, and histopathological examination of the lungs of infected mice revealed marked differences between RB6- and rIgG-treated mice. RB6-treated mice had focal, perivascular lesions without accompanying parenchymal inflammation, and rIgG-treated mice had diffuse, interstitial parenchymal inflammation. Lung homogenates from the rIgG-treated mice had more leukocytes and significantly more total and apoptotic PMNs as determined by fluorescence-activated cell sorter analysis with Annexin V and terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling staining of lung tissue samples. Studies with a pneumolysin-deficient mutant of the serotype 8 strain we used also demonstrated the prolonged survival of RB6- compared to rIgG-treated mice. Taken together, our findings suggest that PMNs enhance the likelihood of early death and alter the pathological response to pneumococcal lung infection in BALB/c mice with serotype 8 pneumonia without significantly affecting bacterial clearance or the cytokine response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296760      PMCID: PMC1865693          DOI: 10.1128/IAI.01579-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  81 in total

1.  Host cellular immune response to pneumococcal lung infection in mice.

Authors:  A Kadioglu; N A Gingles; K Grattan; A Kerr; T J Mitchell; P W Andrew
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Identification of invasive serotype 1 pneumococcal isolates that express nonhemolytic pneumolysin.

Authors:  Lea-Ann S Kirkham; Johanna M C Jefferies; Alison R Kerr; Yu Jing; Stuart C Clarke; Andrew Smith; Tim J Mitchell
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

3.  Flow cytometric identification of murine neutrophils and monocytes.

Authors:  E Lagasse; I L Weissman
Journal:  J Immunol Methods       Date:  1996-10-16       Impact factor: 2.303

4.  Neutrophils in innate immunity.

Authors:  Qin Wang; Claire M Doerschuk; Joseph P Mizgerd
Journal:  Semin Respir Crit Care Med       Date:  2004-02       Impact factor: 3.119

5.  Activation of human complement by the pneumococcal toxin pneumolysin.

Authors:  J C Paton; B Rowan-Kelly; A Ferrante
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

6.  Role of Pneumolysin's complement-activating activity during pneumococcal bacteremia in cirrhotic rats.

Authors:  R B Alcantara; L C Preheim; M J Gentry
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

7.  Role of capsule and interleukin-6 in long-term immune control of Cryptococcus neoformans infection by specifically activated human peripheral blood mononuclear cells.

Authors:  Asna A Siddiqui; Robin J Shattock; Thomas S Harrison
Journal:  Infect Immun       Date:  2006-09       Impact factor: 3.441

8.  Survival of Staphylococcus aureus inside neutrophils contributes to infection.

Authors:  H D Gresham; J H Lowrance; T E Caver; B S Wilson; A L Cheung; F P Lindberg
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

9.  Activation of neutrophils and inhibition of the proinflammatory cytokine response by endogenous granulocyte colony-stimulating factor in murine pneumococcal pneumonia.

Authors:  Sylvia Knapp; Lars Hareng; Anita W Rijneveld; Paul Bresser; Jaring S van der Zee; Sandrine Florquin; Thomas Hartung; Tom van der Poll
Journal:  J Infect Dis       Date:  2004-03-29       Impact factor: 5.226

10.  Role of Toll-like receptor 4 in gram-positive and gram-negative pneumonia in mice.

Authors:  Judith Branger; Sylvia Knapp; Sebastiaan Weijer; Jaklien C Leemans; Jennie M Pater; Peter Speelman; Sandrine Florquin; Tom van der Poll
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

View more
  40 in total

1.  Interleukin-1β regulates CXCL8 release and influences disease outcome in response to Streptococcus pneumoniae, defining intercellular cooperation between pulmonary epithelial cells and macrophages.

Authors:  Helen M Marriott; Kate A Gascoyne; Ravi Gowda; Ian Geary; Martin J H Nicklin; Francesco Iannelli; Gianni Pozzi; Timothy J Mitchell; Moira K B Whyte; Ian Sabroe; David H Dockrell
Journal:  Infect Immun       Date:  2011-12-12       Impact factor: 3.441

2.  Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection.

Authors:  Natalia Muñoz; Laurye Van Maele; Juan M Marqués; Analía Rial; Jean-Claude Sirard; José A Chabalgoity
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

Review 3.  The pneumococcus: epidemiology, microbiology, and pathogenesis.

Authors:  Birgitta Henriques-Normark; Elaine I Tuomanen
Journal:  Cold Spring Harb Perspect Med       Date:  2013-07-01       Impact factor: 6.915

4.  Cytosolic Phospholipase A2α Promotes Pulmonary Inflammation and Systemic Disease during Streptococcus pneumoniae Infection.

Authors:  Rudra Bhowmick; Stacie Clark; Joseph V Bonventre; John M Leong; Beth A McCormick
Journal:  Infect Immun       Date:  2017-10-18       Impact factor: 3.441

5.  Designed reduction of Streptococcus pneumoniae pathogenicity via synthetic changes in virulence factor codon-pair bias.

Authors:  J Robert Coleman; Dimitris Papamichail; Masahide Yano; María Del Mar García-Suárez; Liise-Anne Pirofski
Journal:  J Infect Dis       Date:  2011-02-21       Impact factor: 5.226

6.  The innate immune response to Streptococcus pneumoniae in the lung depends on serotype and host response.

Authors:  Beza Seyoum; Masahide Yano; Liise-anne Pirofski
Journal:  Vaccine       Date:  2011-08-22       Impact factor: 3.641

7.  Macrophage Migration Inhibitory Factor Is Detrimental in Pneumococcal Pneumonia and a Target for Therapeutic Immunomodulation.

Authors:  Jeffrey N Weiser; Aoife M Roche; Christopher B Hergott; Meredith I LaRose; Tarah Connolly; William L Jorgensen; Lin Leng; Richard Bucala; Rituparna Das
Journal:  J Infect Dis       Date:  2015-05-05       Impact factor: 5.226

8.  A serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody requires Fcγ receptor III and macrophages to mediate protection against pneumococcal pneumonia in mice.

Authors:  Sarah Weber; Haijun Tian; Nico van Rooijen; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2012-01-30       Impact factor: 3.441

9.  Allergic Lung Inflammation Reduces Tissue Invasion and Enhances Survival from Pulmonary Pneumococcal Infection in Mice, Which Correlates with Increased Expression of Transforming Growth Factor β1 and SiglecF(low) Alveolar Macrophages.

Authors:  Alan M Sanfilippo; Yoichi Furuya; Sean Roberts; Sharon L Salmon; Dennis W Metzger
Journal:  Infect Immun       Date:  2015-05-11       Impact factor: 3.441

10.  Reactive oxygen species regulate neutrophil recruitment and survival in pneumococcal pneumonia.

Authors:  Helen M Marriott; Laura E Jackson; Thomas S Wilkinson; A John Simpson; Tim J Mitchell; David J Buttle; Simon S Cross; Paul G Ince; Paul G Hellewell; Moira K B Whyte; David H Dockrell
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.